RenovoRx, Inc. (RNXT )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol RNXT
- Company RenovoRx, Inc.
- Price $0.81
- Changes Percentage 8
- Change 0.06
- Day Low $0.77
- Day High $0.86
- Year High $1.69
- Year Low $0.7
- Market Cap $30,001,985
- Price Avg 50 EMA (D) $1.15
- Price Avg 200 EMA (D) $1.14
- Exchange NASDAQ
- Volume 585,016
- Average Volume 571,859
- Open $0.77
- Previous Close $0.75
- EPS -0.38
- PE -2.15
- Earnings Announcement 2026-03-30 04:00:00
- Shares Outstanding $36,645,884
Company brief: RENOVORX, INC. (RNXT )
- Healthcare
- Biotechnology
- Mr. Shaun R. Bagai
- https://renovorx.com
- US
- N/A
- 08-26-2021
- US75989R1077
RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.